{"sequenceId":"845367218698","id":"34207259930","language":"English","title":"Miragen Therapeutics Inc (MGEN) Expected to Announce Earnings of -$0.29 Per Share","content":"Brokerages predict that Miragen Therapeutics Inc (NASDAQ:MGEN) will report earnings of ($0.29) per share for the current quarter, Zacks reports. Three analysts have made estimates for Miragen Therapeutics’ earnings. The lowest EPS estimate is ($0.30) and the highest is ($0.28). Miragen Therapeutics reported earnings per share of ($0.34) during the same quarter last year, which suggests a positive year over year growth rate of 14.7%. The company is expected to issue its next earnings report  on Friday, August 10th.    On average, analysts expect that Miragen Therapeutics will report full-year earnings of ($1.11) per share for the current financial year, with EPS estimates ranging from ($1.30) to ($1.01). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.56) per share, with EPS estimates ranging from ($2.38) to ($1.15). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Miragen Therapeutics.    Miragen Therapeutics (NASDAQ:MGEN) last released its quarterly earnings data on Wednesday, May 9th. The medical research company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.07. Miragen Therapeutics had a negative return on equity of 50.53% and a negative net margin of 290.61%. The business had revenue of $4.78 million during the quarter, compared to analysts’ expectations of $1.17 million.    MGEN has been the subject of a number of research analyst reports. Evercore ISI initiated coverage on Miragen Therapeutics in a research note on Friday, March 9th. They issued an “outperform” rating and a $19.00 target price for the company. Cann  restated a “buy” rating and issued a $13.00 target price on shares of Miragen Therapeutics in a research note on Friday, February 2nd. Jefferies Group initiated coverage on Miragen Therapeutics in a research note on Thursday, March 29th. They issued a “buy” rating and a $14.00 target price for the company. Deutsche Bank initiated coverage on Miragen Therapeutics in a research note on Thursday, March 22nd. They issued a “buy” rating and a $15.00 target price for the company. Finally, Zacks Investment Research upgraded Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a research note on Wednesday, April 18th. One research analyst  has rated the stock with a sell rating, two have issued  a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $16.11.    Miragen Therapeutics traded up $0.25, hitting $7.32, on Friday, according to Marketbeat Ratings . The company’s stock had a trading volume of 57,430 shares, compared to its average volume of 238,141. The stock has a market cap of $219.50 million, a P/E ratio of -5.30 and a beta of 1.32. The company has a debt-to-equity ratio of 0.14, a quick ratio of 20.91 and a current ratio of 20.91. Miragen Therapeutics has a 52-week low of $5.01 and a 52-week high of $15.91.    Several institutional investors and hedge funds have recently added to or reduced their stakes in MGEN. Aveo Capital Partners LLC purchased a new position in shares of  Miragen Therapeutics in the 4th quarter valued at approximately $279,000.  Wells Fargo & Company MN raised its stake in  Miragen Therapeutics by 203.8% during the fourth quarter. Wells Fargo & Company MN now owns 17,804 shares of the medical research company’s stock valued at $185,000 after buying an additional 11,943 shares during the last quarter.  Bank of New York Mellon Corp raised its stake in  Miragen Therapeutics by 67.1% during the fourth quarter. Bank of New York Mellon Corp now owns 45,775 shares of the medical research company’s stock valued at $478,000 after buying an additional 18,374 shares during the last quarter.  BlackRock Inc. raised its stake in  Miragen Therapeutics by 4.7% during the fourth quarter. BlackRock Inc. now owns 574,917 shares of the medical research company’s stock valued at $5,997,000 after buying an additional 25,704 shares during the last quarter.  Finally, Virtu Financial LLC raised its stake in  Miragen Therapeutics by 372.8% during the fourth quarter. Virtu Financial LLC now owns 51,896 shares of the medical research company’s stock valued at $541,000 after buying an additional 40,920 shares during the last quarter. Institutional investors own  33.15% of the company’s stock.    About Miragen Therapeutics    Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan.    Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)    For more information about research offerings from Zacks Investment Research, visit Zacks.com","contentWithMarkup":"Brokerages predict that Miragen Therapeutics Inc (NASDAQ:MGEN) will report earnings of ($0.29) per share for the current quarter, Zacks reports. Three analysts have made estimates for Miragen Therapeutics’ earnings. The lowest EPS estimate is ($0.30) and the highest is ($0.28). Miragen Therapeutics reported earnings per share of ($0.34) during the same quarter last year, which suggests a positive year over year growth rate of 14.7%. The company is expected to issue its next earnings report  on Friday, August 10th.    On average, analysts expect that Miragen Therapeutics will report full-year earnings of ($1.11) per share for the current financial year, with EPS estimates ranging from ($1.30) to ($1.01). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.56) per share, with EPS estimates ranging from ($2.38) to ($1.15). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Miragen Therapeutics.    Miragen Therapeutics (NASDAQ:MGEN) last released its quarterly earnings data on Wednesday, May 9th. The medical research company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.07. Miragen Therapeutics had a negative return on equity of 50.53% and a negative net margin of 290.61%. The business had revenue of $4.78 million during the quarter, compared to analysts’ expectations of $1.17 million.    MGEN has been the subject of a number of research analyst reports. Evercore ISI initiated coverage on Miragen Therapeutics in a research note on Friday, March 9th. They issued an “outperform” rating and a $19.00 target price for the company. Cann  restated a “buy” rating and issued a $13.00 target price on shares of Miragen Therapeutics in a research note on Friday, February 2nd. Jefferies Group initiated coverage on Miragen Therapeutics in a research note on Thursday, March 29th. They issued a “buy” rating and a $14.00 target price for the company. Deutsche Bank initiated coverage on Miragen Therapeutics in a research note on Thursday, March 22nd. They issued a “buy” rating and a $15.00 target price for the company. Finally, Zacks Investment Research upgraded Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a research note on Wednesday, April 18th. One research analyst  has rated the stock with a sell rating, two have issued  a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $16.11.    Miragen Therapeutics traded up $0.25, hitting $7.32, on Friday, according to Marketbeat Ratings . The company’s stock had a trading volume of 57,430 shares, compared to its average volume of 238,141. The stock has a market cap of $219.50 million, a P/E ratio of -5.30 and a beta of 1.32. The company has a debt-to-equity ratio of 0.14, a quick ratio of 20.91 and a current ratio of 20.91. Miragen Therapeutics has a 52-week low of $5.01 and a 52-week high of $15.91.    Several institutional investors and hedge funds have recently added to or reduced their stakes in MGEN. Aveo Capital Partners LLC purchased a new position in shares of  Miragen Therapeutics in the 4th quarter valued at approximately $279,000.  Wells Fargo & Company MN raised its stake in  Miragen Therapeutics by 203.8% during the fourth quarter. Wells Fargo & Company MN now owns 17,804 shares of the medical research company’s stock valued at $185,000 after buying an additional 11,943 shares during the last quarter.  Bank of New York Mellon Corp raised its stake in  Miragen Therapeutics by 67.1% during the fourth quarter. Bank of New York Mellon Corp now owns 45,775 shares of the medical research company’s stock valued at $478,000 after buying an additional 18,374 shares during the last quarter.  BlackRock Inc. raised its stake in  Miragen Therapeutics by 4.7% during the fourth quarter. BlackRock Inc. now owns 574,917 shares of the medical research company’s stock valued at $5,997,000 after buying an additional 25,704 shares during the last quarter.  Finally, Virtu Financial LLC raised its stake in  Miragen Therapeutics by 372.8% during the fourth quarter. Virtu Financial LLC now owns 51,896 shares of the medical research company’s stock valued at $541,000 after buying an additional 40,920 shares during the last quarter. Institutional investors own  33.15% of the company’s stock.    About Miragen Therapeutics    Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan.    Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)    For more information about research offerings from Zacks Investment Research, visit Zacks.com","tags":[],"publishedDate":"2018-06-02T21:54:47Z","harvestDate":"2018-06-02T21:59:39Z","estimatedPublishedDate":"2018-06-02T21:54:47Z","url":"http://ct.moreover.com/?a=34207259930&p=1u0&v=1&x=-JrNSO91V5Luv3yg6-mcvw","originalUrl":"https://zolmax.com/investing/miragen-therapeutics-inc-mgen-expected-to-announce-earnings-of-0-29-per-share/2277431.html","outboundUrls":["https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","https://www.marketbeat.com/","https://www.zacks.com/registration/pfp/?ALERT=zrmodule&ADID=AMERBMN_CONTENT_ZER&skip_rpt_name_check=skip_rpt_name_check&t=MGEN"],"wordCount":"823","dataFormat":"text","duplicateGroupId":"34207259930","media":{"audio":[],"images":[{"url":"https://www.marketbeat.com/logos/signal-genetics-inc-logo.gif"},{"url":"https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=MGEN"}],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Earnings news","group":"Finance"},{"name":"Stockwatch","group":"Finance"}],"companies":[{"name":"Miragen Therapeutics Inc","symbol":"1S1N","exchange":"FRA","isin":"US60463E1038","titleCount":1,"contentCount":22,"primary":true},{"name":"Miragen Therapeutics Inc","symbol":"MGEN","exchange":"NAS","isin":"US60463E1038","titleCount":1,"contentCount":22,"primary":true},{"name":"Bank of New York Mellon Corp","symbol":"BN9","exchange":"DUS","isin":"US0640581007","titleCount":0,"contentCount":2,"primary":false},{"name":"Bank of New York Mellon Corp","symbol":"BN9","exchange":"FRA","isin":"US0640581007","titleCount":0,"contentCount":2,"primary":false},{"name":"Bank of New York Mellon Corp","symbol":"BN9","exchange":"STU","isin":"US0640581007","titleCount":0,"contentCount":2,"primary":false},{"name":"Bank of New York Mellon Corp","symbol":"BN9","exchange":"BER","isin":"US0640581007","titleCount":0,"contentCount":2,"primary":false},{"name":"Bank of New York Mellon Corp","symbol":"BN9","exchange":"MUN","isin":"US0640581007","titleCount":0,"contentCount":2,"primary":false},{"name":"Bank of New York Mellon Corp","symbol":"BK","exchange":"NYS","isin":"US0640581007","titleCount":0,"contentCount":2,"primary":false},{"name":"Bank of New York Mellon Corp","symbol":"BK","exchange":"BUE","isin":"ARDEUT110756","titleCount":0,"contentCount":2,"primary":false},{"name":"Bank of New York Mellon Corp","symbol":"BONY34","exchange":"BSP","isin":"BRBONYBDR001","titleCount":0,"contentCount":2,"primary":false},{"name":"Bank of New York Mellon Corp","symbol":"BK","exchange":"MEX","isin":"US0640581007","titleCount":0,"contentCount":2,"primary":false},{"name":"Bank of New York Mellon Corp","symbol":"BKpC","exchange":"NYS","isin":"US0640582096","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLQA","exchange":"STU","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLQA","exchange":"MUN","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLK","exchange":"MEX","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLQA","exchange":"FRA","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLQA","exchange":"BER","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLK","exchange":"SWX","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLK","exchange":"NYS","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLAK34","exchange":"BSP","isin":"BRBLAKBDR003","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"0QZZ","exchange":"LTS","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLQA","exchange":"ETR","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"BlackRock Inc","symbol":"BLK","exchange":"WBO","isin":"US09247X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"Virtu Financial Inc","symbol":"VIRT","exchange":"NAS","isin":"US9282541013","titleCount":0,"contentCount":2,"primary":false},{"name":"Virtu Financial Inc","symbol":"0VF","exchange":"BER","isin":"US9282541013","titleCount":0,"contentCount":2,"primary":false},{"name":"Virtu Financial Inc","symbol":"0VF","exchange":"STU","isin":"US9282541013","titleCount":0,"contentCount":2,"primary":false},{"name":"Virtu Financial Inc","symbol":"0VF","exchange":"FRA","isin":"US9282541013","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"STU","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"BER","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"MUN","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"HAM","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"DUS","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"FRA","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"SWX","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"ETR","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCNP","exchange":"PINX","isin":"US9497468879","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"NYS","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"SGO","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"MEX","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"LIM","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCO34","exchange":"BSP","isin":"BRWFCOBDR009","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"BUE","isin":"ARDEUT110434","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"HAN","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpV","exchange":"NYS","isin":"US94988U7303","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpR","exchange":"NYS","isin":"US9497464654","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpW","exchange":"NYS","isin":"US94988U7147","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpO","exchange":"NYS","isin":"US9497467210","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpY","exchange":"NYS","isin":"US94988U6560","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpN","exchange":"NYS","isin":"US9497467475","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpJ","exchange":"NYS","isin":"US9497468796","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpX","exchange":"NYS","isin":"US94988U6727","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpL","exchange":"NYS","isin":"US9497468044","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpP","exchange":"NYS","isin":"US9497466550","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpT","exchange":"NYS","isin":"US9497463664","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpQ","exchange":"NYS","isin":"US9497465560","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"WBO","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Capital Partners SA","symbol":"CPA","exchange":"WAR","isin":"PLCPTLP00015","titleCount":0,"contentCount":1,"primary":false},{"name":"Capital Partners SA","symbol":"0LSM","exchange":"LTS","isin":"PLCPTLP00015","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"FRA","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"HAN","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"MUN","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"DUS","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"STU","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"HAM","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"BER","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"SWX","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"ETR","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DB","exchange":"NYS","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"BSE","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBN","exchange":"MEX","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"0H7D","exchange":"LTS","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"MIL","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false}],"author":{"name":"Stuart Ham","publishingPlatform":{}},"licenses":[{"name":"CLA"}],"source":{"name":"Zolmax News","homeUrl":"http://zolmax.com","category":"National","editorialRank":"3","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"379974975","name":"Zolmax News","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"0"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Standard","News"],"genre":"General"}},"es_id":86994695}